يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"mutated non–small-cell lung cancer (NSCLC)"', وقت الاستعلام: 0.90s تنقيح النتائج
  1. 1
    دورية أكاديمية
    EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP)

    المؤلفون: Corrales, Luis, Ordóñez-Reyes, Camila, Barron, Lucia Zatarain, Martín, Claudio Marcelo, Barrón-Barrón, Feliciano, Ruíz-Patiño, Alejandro, Recondo, Gonzalo, Rojas, Leonardo, Sotelo, Carolina, Rodríguez, July F., Cardona, Andrés Felipe, Garcia-Robledo, Juan Esteban

    المساهمون: Cardona, Andrés Felipe 0000-0003-3525-4126, Garcia-Robledo, Juan Esteban 0000-0003-2912-152X

    مصطلحات موضوعية: Pacientes con receptor del factor de crecimiento epidérmico (EGFR), Cáncer de pulmón de células no pequeñas (CPCNP) mutado, Polimorfismo de eliminación BIM (eliminación BIM), Patients with epidermal growth factor receptor (EGFR), mutated non–small-cell lung cancer (NSCLC), harboring BIM deletion polymorphism (BIM deletion)

    وصف الملف: application/pdf

    العلاقة: JCO Precision Oncology, 2473-4284, Vol 5, 2021, pag 839-848; http://hdl.handle.net/20.500.12495/7299Test; https://doi.org/10.1200/PO.20.00404Test; instname:Universidad El Bosque; reponame:Repositorio Institucional Universidad El Bosque; repourl:https://repositorio.unbosque.edu.coTest

    الإتاحة: https://doi.org/20.500.12495/7299Test
    https://doi.org/10.1200/PO.20.00404Test
    https://hdl.handle.net/20.500.12495/7299Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP)

    المؤلفون: Tatiana Gamez, Carlos Vargas, Christian Rolfo, Pilar Archila, Luis Corrales, Oscar Arrieta, Claudio Martin, Jorge Otero, C. Sotelo, Hernán Carranza, Juan Esteban Garcia-Robledo, D. Mayorga, Luisa Ricaurte, Camila Ordóñez-Reyes, Lucia Zatarain Barron, L. Rojas, Rafael Rosell, Luis Mas, Alejandro Ruiz-Patiño, Maritza Bermudez, July Rodriguez, J. Ávila, Andrés F. Cardona, Gonzalo Recondo, Feliciano Barrón

    المساهمون: Cardona, Andrés Felipe [0000-0003-3525-4126], Garcia-Robledo, Juan Esteban [0000-0003-2912-152X]

    المصدر: Repositorio U. El Bosque
    Universidad El Bosque
    instacron:Universidad El Bosque

    مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Lung Neoplasms, Bevacizumab, First line, Pacientes con receptor del factor de crecimiento epidérmico (EGFR), Patients with epidermal growth factor receptor (EGFR), Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, harboring BIM deletion polymorphism (BIM deletion), Carcinoma, Non-Small-Cell Lung, medicine, Humans, mutated non–small-cell lung cancer (NSCLC), Epidermal growth factor receptor, Lung cancer, Aged, Neoplasm Staging, Retrospective Studies, EGFR inhibitors, Polimorfismo de eliminación BIM (eliminación BIM), Polymorphism, Genetic, Bcl-2-Like Protein 11, biology, business.industry, Kinase, Middle Aged, medicine.disease, respiratory tract diseases, ErbB Receptors, Drug Combinations, 030104 developmental biology, Oncology, Apoptosis, Egfr mutation, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Female, business, Gene Deletion, Cáncer de pulmón de células no pequeñas (CPCNP) mutado, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f368f60a7559c0ff0c3e0f742a7de86eTest
    https://doi.org/10.1200/po.20.00404Test


    أضف إلى المفضلة
  3. 3
    تقرير
    An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

    المساهمون: Lu shun, Vice-chairman

    المصدر: Gross ME, Shazer RL, Agus DB. Targetg the HER-kase ax cancer. Sem Oncol. 2004 Feb;31(1 Suppl 3):9-20. do 10.1053/j.semoncol.2004.01.005.
    Barnes CJ, Kumar R. Epermal growth factor receptor famy tyrose kases as snal tegrators and therapeut targets. Cancer Metastas Rev. 2003 Dec;22(4):301-7. do 10.1023/a:1023726827771.
    Arteaga C. Targetg HER1/EGFR: a molecular approach to cancer therapy. Sem Oncol. 2003 Jun;30(3 Suppl 7):3-14.
    Baselga J, Hammond LA. HER-targeted tyrose-kase hors. Oncology. 2002;63 Suppl 1:6-16. do 10.1159/000066198.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Sao N, Sunpaweravong P, Han B, Margono B, hose Y, NhakY, Ohe Y, Yang JJ, Chewaskulyong B, Jng H, Duffld EL, Watks CL, Armour AA, Fukuoka M. Gef or carboplat-paclaxel pulmonary adenocarcoma. N Engl J Med. 2009 Sep 3;361(10):947-57. do 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
    Roberts PJ, Stchcombe TE, Der CJ, SocskMA. Personaled mede non-small-cell lung cancer: KRAS a useful marker selectg patnts for epermal growth factor receptor-targeted therapy? J Cl Oncol. 2010 Nov 1;28(31):4769-77. do 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4.
    Ramalgam SS, Blackhall F, KrzakowskM, Barrs CH, Park K, Bover Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ru-Garc A, Taylor Lng JQ, Campbell AK, O'Connell J, Boyer M. Randomed phase study of dacom (PF-00299804), an reversle pan-human epermal growth factor receptor hor, versus erlot patnts wh advanced non-small-cell lung cancer. J Cl Oncol. 2012 Sep 20;30(27):3337-44. do 10.1200/JCO.2011.40.9433. Epub 2012 Jul 2.
    Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, No S, TsujF, Lke R, Rosell R, Corral J, Mlro MR, PluzanskA, Sbar E Wang T, Whe JL, Nadanaca S, Sand R, Mok TS. Dacom versus gef as fst-le treatment for patnts wh EGFR-mutatn-pose non-small-cell lung cancer (ARCHER 1050): a randomed, open-label, phase 3 trl. Lancet Oncol. 2017 Nov;18(11):1454-1466. do 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
    Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, No S, Lee M, Lke R, Rosell R, Corral J, Mlro MR, PluzanskA, Sbar E Wang T, Whe JL, Wu YL. provement Overall Surval a Randomed Study That Compared Dacom Wh Gef Patnts Wh Advanced Non-Small-Cell Lung Cancer and EGFR-Actatg Mutatns. J Cl Oncol. 2018 Aug 1;36(22):2244-2250. do 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4. Erratum : J Cl Oncol. 2020 Nov 1;38(31):3725.
    Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, Huang YS, Yan HH, Ren S, L Y, Yang JJ. Erlot as second-le treatment patnts wh advanced non-small-cell lung cancer and asymptomat bra metastases: a phase study (CTONG-0803). Ann Oncol. 2013 Apr;24(4):993-9. do 10.1093/annonc/mds529. Epub 2012 Nov 4.
    Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, L X, Yan HH, Tan FL, Zhong W, Wu YL. ot versus whole-bra radtn patnts wh EGFR-mutant non-small-cell lung cancer and multle bra metastases (BRA): a multentre, phase 3, open-label, parallel, randomed controlled trl. Lancet Resp Med. 2017 Sep;5(9):707-716. do 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.
    Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, BertolA, Bohnet S, Zhou C, Lee KH, NogamN, Okamoto Lehl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalgam SS, Vansteenkte J. CNS Response to Osert Versus Standard Epermal Growth Factor Receptor Tyrose Kase hors Patnts Wh Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Cl Oncol. 2018 Aug 28:JCO2018783118. do 10.1200/JCO.2018.78.3118. Onle ahead of prt.
    An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04339829Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث